Draft:Stellah George Mpagama
Tanzanian physician-scientist
From Wikipedia, the free encyclopedia
Stellah George Mpagama is a Tanzanian physician-scientist, and tuberculosis researcher based at Kibong’oto Hospital in Tanzania. Her research focuses on tuberculosis treatment, multidrug-resistant TB, TB/HIV, infectious disease clinical trials. She has been involved in EDCTP-supported tuberculosis research programmes, including the PanACEA network and OptiRiMoxTB clinical trial. In 2022, she received the Dr Maria Kamm Best Female Scientist Award, and in 2026 Global Health EDCTP3.[1] included her among ten EDCTP-supported researchers profiled for their work in global health.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Submission declined on 11 July 2026 by ChrysGalley (talk). This draft appears to contain text generated by a large language model (such as ChatGPT). You cannot use LLMs to generate, draft, or rewrite article content.
Please delete the portions which were LLM-generated, and summarize in your own words a range of independent, reliable, published sources that discuss the subject. If you have used an LLM but you believe that your use is covered by one of the two exceptions (basic copyediting and translation between two languages in which you are fully fluent), please provide a transcript of the prompt(s) you used while writing your draft (see the how-to guide). Reviewers can make mistakes. If you have not received any LLM assistance, you may seek a second opinion at the AfC Help Desk. See the advice page on large language models for more information.This draft's references do not show that the subject meets Wikipedia's criteria for inclusion for academics. The draft requires either:
Declined by ChrysGalley 3 months ago.
or multiple published secondary sources that:
| |
Comment: Early life and education section is uncited, we have strict requirements for WP:Biographies of living persons TNM101 (in solidarity · chat) 15:11, 18 August 2026 (UTC)
- Comment: The LLM text seems much less. However, there are not enough independent sources talking about this researcher. Try looking at her institution(s) to see if they have links to newspaper or book coverage of her. (The institutions are not independent, but can be a good place to start looking.) M kuhner (talk) 03:19, 15 August 2026 (UTC)
- Comment: We can't accept AI drafts. In addition there isn't an obvious criteria of WP:NACADEMIC that is being met here. ChrysGalley (talk) 08:55, 11 July 2026 (UTC)
Stellah George Mpagama | |
|---|---|
| Education | University of Dar es Salaam; Kilimanjaro Christian Medical University College |
| Awards | Dr Maria Kamm Best Female Scientist Award; EDCTP Senior Fellowship |
| Scientific career | |
| Fields | Tuberculosis research; infectious diseases; clinical trials; implementation science |
| Workplaces | Kibong’oto Infectious Diseases Hospital |
Early Life and Education
Mpagama earned her Doctor of Medicine (MD) from the University of Dar es Salaam in 2005. She completed a Master of Science in clinical research at Kilimanjaro Christian Medical University College in 2010, and a PhD in medicine at the same institution in 2014.[citation needed]
Career and Research
Mpagama is based at Kibong’oto Infectious Diseases Hospital in Kilimanjaro, Tanzania, where her research has focused on tuberculosis treatment, TB/HIV co-infection and multidrug-resistant tuberculosis. Her early publications examined diagnosis and treatment outcomes among multidrug-resistant tuberculosis patients in Tanzania, including studies on diagnostic delays, molecular testing.[2]
She has participated in EDCTP-supported tuberculosis research programmes, including the PanACEA Consortium[3], which evaluated alternative treatment regimens. In 2018 received an EDCTP Senior Fellowship as project lead at Kibong’oto Infectious Diseases Hospital[4] for work on preventing kanamycin related hearing loss among patients treated for multidrug-resistant tuberculosis.[5]
Mpagama is a principal investigator of the OptiRimoxTB trial, part of the EDCTP-funded SimpliciTB project, which evaluates shortened treatment regimens for drug-susceptible pulmonary tuberculosis.[6] Her other research has included post-tuberculosis lung disease and molecular bacterial load assays for distinguishing active tuberculosis from post-TB lung disease.
Awards, Fellowships and Memberships
Mpagama received the Dr Maria Kamm Best Female Scientist Award in 2022[7], presented by the National Institute for Medical Research during the 2nd Annual Joint Scientific Conference in Dar es Salaam.
She received an EDCTP Senior Fellowship in 2018.[4] for research on multidrug-resistant tuberculosis. In 2026, Global Health EDCTP3 included her among ten EDCTP-supported researchers profiled for their work in global health.[1]
Selected Publications
- Mpagama, Stellah G.; Mbelele, Peter M.; Chongolo, Anna M.; Lekule, Isaack A.; Lyimo, Johnson J.; Kibiki, Gibson S.; Heysell, Scott K. (11 April 2019). "Gridlock from diagnosis to treatment of multidrug-resistant tuberculosis in Tanzania: low accessibility of molecular diagnostic services and lack of healthcare worker empowerment in 28 districts of 5 high burden TB regions with mixed methods evaluation". BMC Public Health. 19 (1) 395. doi:10.1186/s12889-019-6720-6. PMC 6458695. PMID 30971228.
- Mpagama, Stellah G.; Msaji, Kassim S.; Kaswaga, Oscar L.; Zurba, Lindsay J.; Mbelele, Peter M.; Allwood, Brian W.; Ngungwa, B. S.; Kisonga, Riziki M.; Lesosky, Maia; Rylance, Jamie; Mortimer, Kevin (1 October 2021). "The burden and determinants of post-TB lung disease". The International Journal of Tuberculosis and Lung Disease. 25 (10): 846–853. doi:10.5588/ijtld.21.0278. PMC 8504494. PMID 34615582.
- Mbelele, Peter M.; Sabiiti, Wilber; Heysell, Scott K.; Sauli, Elingarami; Mpolya, Emmanuel A.; Mfinanga, Sayoki; Gillespie, Stephen H.; Addo, Kennedy K.; Kibiki, Gibson; Sloan, Derek J.; Mpagama, Stellah G. (1 March 2022). "Use of a molecular bacterial load assay to distinguish between active TB and post-TB lung disease". The International Journal of Tuberculosis and Lung Disease. 26 (3): 276–278. doi:10.5588/ijtld.21.0459. PMC 8886960. PMID 35197168.
- Boeree, Martin J.; Heinrich, Norbert; Aarnoutse, Rob E.; Diacon, Andreas H.; Dawson, Rodney; Rehal, Sunita; Kibiki, Gibson S.; Churchyard, Gavin; Sanne, Ian; Ntinginya, Nyanda E.; Semvua, Hadija H.; Mpagama, Stellah G.; Gillespie, Stephen H.; Phillips, Patrick P. J.; Hoelscher, Michael (January 2017). "High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial". The Lancet Infectious Diseases. 17 (1): 39–49. doi:10.1016/S1473-3099(16)30274-2. PMC 5159618. PMID 28100438.
- Reliable sources include: reputable newspapers, magazines, academic journals, and books from respected publishers.
- Unacceptable sources include: personal blogs, social media, predatory publishers, most tabloids, and websites where anyone can contribute.
Replace any unreliable sources with high-quality sources. If you cannot find a reliable source for the material, it should be removed.